Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Active not recruiting 3Recruiting 2Withdrawn 1Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × GRN163L peptide × Clear all
NCT01836549 2018-07-20

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Pediatric Brain Tumor Consortium

Phase 2 Terminated
43 enrolled 14 charts
CNSSarcoma

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡